Wednesday, June 10, 2026

Patent intelligence · PT

PT 2303855

CATALYTIC PROCESS FOR ASYMMETRIC HYDROGENATION

granted A61P/4300A61P/900A61P/910
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 9
Applicant portfolio 21
Patent details — PT 2303855

Quick answer

PT 2303855 (CATALYTIC PROCESS FOR ASYMMETRIC HYDROGENATION) is held by BIAL PORTELA & Cª S A [PT]. Status: granted. Granted Mar 11, 2015. Expires Mar 6, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
CPC classes
A61P/4300, A61P/900, A61P/910

More from BIAL PORTELA & Cª S A [PT]

Related pharmaceutical patents in our USPTO index.

  1. WO 2022081033

    OPICAPONE ET LÉVODOPA POUR LE TRAITEMENT DE LA MALADIE DE PARKINSON

    BIAL PORTELA & Cª S A [PT] · Expires Apr 16, 2042

    granted
  2. WO 2022025781

    DISPERSION SOLIDE D'OPICAPONE

    BIAL PORTELA & Cª S A [PT] · Expires Jan 29, 2042

    granted
  3. WO 2021182981

    OPICAPONE MICRONISÉE

    BIAL PORTELA & Cª S A [PT] · Expires Sep 11, 2041

    granted
  4. WO 2020246903

    INHIBITEURS DE DOPAMINE-B-HYDROXYLASE

    BIAL PORTELA & Cª S A [PT] · Expires Dec 5, 2040

    granted
  5. AU 2018379646

    Dopamine-B-hydroxylase inhibitors

    BIAL PORTELA & Cª S A [PT] · Expires Jun 6, 2040

    granted
  6. BR PI0923819

    compostos farmacêuticos

    BIAL PORTELA & Cª S A [PT] · Expires Nov 14, 2039

    granted
  7. EP 3515433

    DIE BLUT-HIRN-SCHRANKE PASSIERENDE DOPAMIN-B-HYDROXYLASE-INHIBITOREN

    BIAL PORTELA & Cª S A [PT] · Expires Jul 26, 2039

    granted
  8. US 2019008774

    PHARMACEUTICAL FORMULATIONS COMPRISING NITROCATECHOL DERIVATIVES AND METHODS OF MAKING THE SAME

    BIAL PORTELA & Cª S A [PT] · Expires Jan 5, 2039

    granted

Frequently asked questions

What is US patent 2303855?

PT 2303855 (CATALYTIC PROCESS FOR ASYMMETRIC HYDROGENATION) is held by BIAL PORTELA & Cª S A [PT]. Status: granted. Granted Mar 11, 2015. Expires Mar 6, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.

Who owns PT 2303855?

BIAL PORTELA & Cª S A [PT] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 21 pharmaceutical patents for this assignee.

When does PT 2303855 expire?

Our index shows an expiration date of Mar 6, 2035 (9 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.